This database contains 163 studies, archived under the term: "Other"
Click here to filter this large number of results.
A randomized double-blind trial of the effects of hormone therapy on delayed verbal recall in older women
Tierney, Mary C.,
Oh, Paul,
Moineddin, Rahim,
Greenblatt, Ellen M.,
Snow, W. Gary,
Fisher, Rory H.,
Iazzetta, John,
Hyslop, Peter St George,
MacLusky, Neil J.
We examined whether estradiol and norethindrone hormone therapy (HT) prevented decline in delayed verbal recall in older women with normal to mildly impaired memory functioning. This was a 2-year, randomized, double-blind, placebo-controlled trial of 142 women aged 61-87, randomly assigned to receive 1 mg 17-beta estradiol daily and 0.35 mg norethindrone 3 days/week or daily […]
Rosiglitazone monotherapy in mild-to-moderate Alzheimer’s disease: results from a randomized, double-blind, placebo-controlled phase III study
Gold, Michael,
Alderton, Claire,
Zvartau-Hind, Marina,
Egginton, Sally,
Saunders, Ann M.,
Irizarry, Michael,
Craft, Suzanne,
Landreth, Gary,
Linnamägi, Ulla,
Sawchak, Sharon
Background/aims: A phase II study of the peroxisome proliferator-activated receptor-γ agonist rosiglitazone extended release (RSG XR) in mild-to-moderate Alzheimer’s disease (AD) detected a treatment benefit to cognition in apolipoprotein E(APOE)-ε4-negative subjects. The current phase III study with prospective stratification by APOE genotype was conducted to confirm the efficacy and safety of RSG XR in mild-to-moderate […]
A randomized, placebo-controlled trial of latrepirdine in Huntington disease
Kieburtz, Karl,
McDermott, Michael P.,
Voss, Tiffini S.,
Corey-Bloom, Jody,
Deuel, Lisa M.,
Dorsey, E. Ray,
Factor, Stewart,
Geschwind, Michael D.,
Hodgeman, Karen,
Kayson, Elise,
Noonberg, Sarah,
Pourfar, Michael,
Rabinowitz, Karen,
Ravina, Bernard,
Sanchez-Ramos, Juan,
Seely, Lynn,
Walker, Francis,
Feigin, Andrew
Objectives: To evaluate the safety and tolerability of latrepirdine in Huntington disease (HD) and explore its effects on cognition, behavior, and motor symptoms.; Design: Double-blind, randomized, placebo-controlled trial.; Setting: Multicenter outpatient trial.; Participants: Ninety-one participants with mild to moderate HD enrolled at 17 US and UK centers from July 18, 2007, through July 16, 2008.; […]
Quality of life in nursing home residents with advanced dementia
Objectives: To examine quality of life (QOL) in nursing home (NH) residents with advanced dementia and identify correlates of QOL near the end of life.; Design: Cross-sectional data derived from NH records, interviews with residents’ surrogate decision-makers, QOL ratings by NH caregivers, and assessment of residents’ cognitive function.; Setting: Three NHs in Maryland.; Participants: A […]
Autoimmune dementia: clinical course and predictors of immunotherapy response
Flanagan, Eoin P.,
McKeon, Andrew,
Lennon, Vanda A.,
Boeve, Bradley F.,
Trenerry, Max R.,
Tan, K. Meng,
Drubach, Daniel A.,
Josephs, Keith A.,
Britton, Jeffrey W.,
Mandrekar, Jayawant N.,
Lowe, Val,
Parisi, Joseph E.,
Pittock, Sean J.
Objective: To define the diagnostic characteristics and predictors of treatment response in patients with suspected autoimmune dementia.; Patients and Methods: Between January 1, 2002, and January 1, 2009, 72 consecutive patients received immunotherapy for suspected autoimmune dementia. Their baseline clinical, radiologic, and serologic characteristics were reviewed and compared between patients who were responsive to immunotherapy […]
EHT0202 in Alzheimer’s disease: a 3-month, randomized, placebo-controlled, double-blind study
Vellas, B.,
Sol, O.,
Snyder, P. J.,
Ousset, P. J.,
Haddad, R.,
Maurin, M.,
Lemarié, J. C.,
Désiré, L.,
Pando, M. P.
Background: EHT0202 (etazolate hydrochloride) is a new compound exhibiting both potential disease-modifying and symptomatic treatment properties in Alzheimer’s Disease increasing alpha-secretase activity and sAPP alpha secretion, as well as acting as a GABA-A receptor modulator and as a PDE-4 inhibitor.; Methods: This pilot, randomized, double-blind, placebo-controlled, parallel group, multicentre, Phase IIA study was conducted in […]
Mibampator (LY451395) randomized clinical trial for agitation/aggression in Alzheimer’s disease
Trzepacz, Paula T.,
Cummings, Jeffrey,
Konechnik, Thomas,
Forrester, Tammy D.,
Chang, Curtis,
Dennehy, Ellen B.,
Willis, Brian A.,
Shuler, Catherine,
Tabas, Linda B.,
Lyketsos, Constantine
Background: Mibampator, an amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptor potentiator, was evaluated for treatment of agitation and aggression (A/A) in Alzheimer’s disease (AD).; Methods: Outpatients (n = 132) with probable AD and A/A randomized to 12 weeks of double-blind treatment with 3-mg po mibampator or placebo were assessed using the 4-domain A/A subscale of the Neuropsychiatric Inventory […]